euroPLX 59 2015

euroPLX cycles facilitate continuous business development and pharma deals since 20 years. Each cycle culminates in a conference after an extensive period of information exchange between registrants who seek and offer business opportunities.

euroPLX cycles are typically attended by business development decision makers, CEOs, owners, vice presidents, directors, and BD&L managers with decision power of drug developing, producing or marketing companies who look for new business opportunities. Brokers or consultants are admitted provided that they have clear, relevant mandates. euroPLX delivers an average of 23 to 27 or more pre-scheduled appointments per participating company.

Partnering scope: Registrants determine the "Dynamic Partnering Focus" of this cycle and conference. It evolves and changes over time within a range from patented to generic (incl. biosimilars), from prescription to OTC drugs, companion diagnostics, nutraceuticals, and medical devices: development, licensing, marketing, promotion, and distribution. It will be displayed on this page as soon as a sufficient number of collaboration interests are submitted

In addition, attending companies may offer or look for R&D services, supporting technologies (new drug delivery; medical devices), contract manufacture, and, to some extent, the supply of APIs and intermediates.